GALT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Galectin Therapeutics Inc (GALT) does not present a strong buy opportunity for a beginner investor with a long-term strategy at this time. While the analyst rating and price target increase are positive, the financial performance is weak, and there are no significant trading or news catalysts to support a strong upward movement. The technical indicators are neutral, and there are no proprietary trading signals to suggest immediate action.
The MACD is positive but contracting, RSI is neutral at 50.207, and moving averages are converging, indicating no clear trend. Key support is at 2.907, and resistance is at 3.258. The stock is trading near its pivot point at 3.083, showing limited momentum.
H.C. Wainwright raised the price target from $6 to $11 with a Buy rating, citing confidence in the company's metabolic dysfunction-associated steatohepatitis program.
Weak financial performance with a significant YoY drop in net income (-26.83%) and EPS (-27.78%). No recent news or significant insider/hedge fund trading activity. Congress trading data is also unavailable.
In Q3 2025, revenue remained at $0 with no growth. Net income dropped to -$8.22M (-26.83% YoY), and EPS declined to -$0.13 (-27.78% YoY). Gross margin remained at 0%.
H.C. Wainwright analyst Matthew Keller raised the price target to $11 from $6 and maintained a Buy rating, citing positive biomarker data for the company's key program.
